

Drug and Dose Range	Proposed Mechanism of Action	Uses*
<b>NMDA-Ca Channel Blocker</b>		
<b>Ketamine</b> 5-10%	Blocks peripheral NMDA receptors to prevent pain transmission from periphery to the brain. This ultimately "turns off" the positive feedback pain loop involved in chronic pain.  - <b>Ketamine</b> : highest affinity for NMDA receptor; also blocks peripheral 5-HT (serotonin) and opioid receptors and edema response to inflammation.	<ul style="list-style-type: none"> <li>•Neuropathic Pain Standard</li> <li>•Chronic Pain - all types</li> <li>•Diabetic Peripheral Neuropathy</li> <li>•Allodynia and Hyperalgesia</li> <li>•Complex Regional Pain Syndrome</li> <li>•Post-op Neuropathic Pain</li> <li>•Lumbar Radiculopathy</li> <li>•Post-herpetic Neuralgia</li> </ul>
<b>Sodium and Glutamate Blockers</b>		
<b>Lidocaine</b> 1-10%	Blocks Na channel in hyperexcited neurons to decrease synaptic efficiency of both NMDA and AMPA (glutamate) receptors in periphery.	•Neuropathic and Inflammatory Pain
<b>Gabapentin</b> 5-10%	Especially useful in diminishing pain transmission in damaged neurons  - <b>Gabapentin</b> : may also block glutamate at NMDA receptor	•Neuropathic Pain Standard
<b>Tricyclic Antidepressants</b>		
<b>Amitriptyline</b> 2-10%	NE and 5-HT reuptake blocker; binds opioid receptors; blocks histamine, peripheral alpha-adrenergic and muscarinic receptors; blocks NMDA receptors and Na channels; interacts with adenosine  - <b>Amitriptyline</b> : has more potent local anesthetic effects than bupivacaine  - <b>Imipramine</b> and <b>desipramine</b> more selective for NE - potential advantage  - <b>Cyclobenzaprine</b> : structure similar to amitriptyline	<ul style="list-style-type: none"> <li>•Neuropathic Pain</li> <li>•Diabetic Neuropathy</li> <li>•Post Herpetic Neuralgia</li> <li>•Chronic Inflammatory Pain</li> <li>•Fibromyalgia</li> <li>•Idiopathic Neuropathy</li> <li>•TMJ Pain</li> </ul>
<b>Imipramine</b> 2-10%		
<b>Cyclobenzaprine</b> 2%		<ul style="list-style-type: none"> <li>•Same as above</li> <li>•Muscle Relaxant</li> </ul>
<b>GABA-B Agonist</b>		
<b>Baclofen</b> 2%	Activates the GABA-B receptor which produces a neuron inhibitory effect	<ul style="list-style-type: none"> <li>•Muscle Relaxant</li> <li>•Fibromyalgia Standard</li> <li>•TMJ Pain</li> </ul>

Drug and Dose Range	Proposed Mechanism of Action	Uses*
<b>Alpha-2 Agonist</b>		
<b>Clonidine</b> <b>0.2%</b>	Blocks NE release to prevent activation of peripheral adrenergic receptors (offers pain relief without loss of sensation seen with anesthetics)	<ul style="list-style-type: none"> <li>•Neuropathic Pain Standard</li> <li>•Sympathetically Maintained</li> <li>•CRPS/Trigeminal Neuralgia</li> <li>•Phantom Limb Pain</li> </ul>
<b>Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)</b>		
<b>Ketoprofen</b> <b>10%</b>	Decreases pain receptor sensitivity by blocking production of prostaglandin 2	<ul style="list-style-type: none"> <li>•Musculoskeletal Pain</li> <li>•Joint Pain</li> <li>•Osteoarthritis</li> <li>•Rheumatoid Arthritis</li> <li>•Soft Tissue Injury</li> <li>•Fibromyalgia</li> <li>•Post-Herpetic Neuralgia</li> <li>•Complex Regional Pain Syndrome</li> <li>•Foot Pain</li> <li>•Sports Injury</li> <li>•Tennis Elbow</li> </ul>
<b>Diclofenac</b> <b>2-10%</b>		<ul style="list-style-type: none"> <li>•Same as above</li> <li>•Particularly used for Acute Pain</li> </ul>
<b>Ketorolac</b> <b>0.5%</b>		<b>Calcium Channel Blocker</b>
<b>Nifedipine</b> <b>2-16%</b>	Increase blood flow to affected area	<ul style="list-style-type: none"> <li>•Diabetic Neuropathy</li> <li>•Increase Circulation</li> </ul>
<b>Verapamil</b> <b>6%</b>		<ul style="list-style-type: none"> <li>•Fibrosis/Scarring</li> </ul>

\* The conditions listed in the “uses” column are NOT FDA-approved, but rather clinical observations